Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Print: 2151-8017
ISSN Online: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015013931
pages 1-5

Rituxan: The First 20 Years

Roland Newman
Tanabe Research Labs USA, 4540 Towne Centre Court, San Diego, California 92121


Rituximab (Rituxan) was the first chimeric monoclonal antibody approved by the Food and Drug Administration (FDA) and the first approved for the treatment of cancer. Since then, combination therapy with various chemotherapeutic agents has increased response rates in lymphoma to almost 100% and has resulted in many cures. After its approval in 1997 for "relapsed or refractory, B-cell, low-grade, or follicular non-Hodgkin's lymphoma", Rituxan has subsequently been approved for other hematological indications as well as for use in several autoimmune diseases, including rheumatoid arthritis. Not only was Rituxan successful in treating lymphoma, but it also overcame the prevailing myth at that time, that monoclonal antibodies were not useful as therapeutics. It also opened the door for future development of many more monoclonal antibodies for treating cancer.

Articles with similar content:

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Krishna Patel, Maya Nair, Riyaz Basha, Sohail Siraj, Jamboor K. Vishwanatha, Chloe Smith
Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Vinod Prabhu, Venugopal Vinod Prabhu
Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 3-4
Elizabeth Lawlor, Poul H. Sorensen
Clinical Significance of the Inhibition of YY1 Activity and Expression by Therapeutic Anti-Cancer Antibodies
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
Sara Huerta-Yepez, Demetrios A. Spandidos, Norio Uematsu, Mario I. Vega, Loredana Militello, Ali R. Jazirehi, Stavroula Baritaki, Benjamin Bonavida
Phage Therapy against Streptococcus pneumoniae: Modern Tool to Control Pneumonia
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Muhammad Imran Qadir, Sahir Sajjad